**The effect of dapagliflozin on albuminuria in the DECLARE-TIMI 58 trial**

Ofri Mosenzon MD MSc1, Stephen D Wiviott MD2, Hiddo H J Heerspink PhD3, Jamie P Dwyer MD4, Avivit Cahn MD1, Erica L Goodrich MS2, Aliza Rozenberg MA1, Meir Schechter MSc1, Ilan Yanuv MSc1, Sabina A Murphy MPH2, Thomas A Zelniker MD MSc 2,5, Ingrid A M Gause-Nilsson MD6, Anna Maria Langkilde MD6, Martin Fredriksson MD6, Peter A Johansson MSc6, Deepak L Bhatt MD MPH 2, Lawrence A Leiter MD7, Darren K McGuire MD8, John P H Wilding MD9,  Marc S Sabatine MD2, Itamar Raz MD1

1 The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

2 TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

3 University Medical Center Groningen, University of Groningen, Groningen, Netherlands and The George Institute for International Health, Sydney, Australia

4 Vanderbilt University Medical Center, Nashville, TN, USA.

5 Division of Cardiology, Medical University of Vienna, Austria

6 Bio Pharmaceuticals R&D, AstraZeneca Gothenburg, Sweden

7Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Ontario, Canada

8Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA and Parkland Health and Hospital System

9Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom

**Key words:** Type 2 diabetes; Dapagliflozin; SGLT2i; Diabetic kidney disease; Prevention; Urinary albumin to creatinine ratio (UACR).

Running title: Albuminuria in the DECLARE-TIMI 58

**Supplementary materials**

**Table S1**: Distribution of categorical UACR at baseline and 6 months’ time points in dapagliflozin vs. placebo arm.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Visit** | **UACR categories** | **Dapagliflozin** | | **Placebo** | |  |
| **N** | **%** | **N** | **%** | **P-value** |
| **Baseline** | ≤15 mg/g | 4381 | 54.0% | 4346 | 54.0% | **0.9899** |
| 15-<30 mg/g | 1240 | 15.3% | 1244 | 15.4% |
| ≥30-≤300 mg/g | 1942 | 23.9% | 1915 | 23.8% |
| >300 mg/g | 555 | 6.8% | 549 | 6.8% |
| **6 months** | ≤15 mg/g | 4508 | 55.7% | 4168 | 51.8% | **<0.0001** |
| 15-<30 mg/g | 1317 | 16.3% | 1246 | 15.5% |
| ≥30-≤300 mg/g | 1853 | 22.9% | 2019 | 25.1% |
| >300 mg/g | 412 | 5.1% | 591 | 7.3% |

Legends: Participants distribution within the UACR categories at baseline and at 6 months, among those with readings at both time points. Comparison between treatment arms was performed using the χ² test. UACR – Urinary Albumin to Creatinine Ratio

**Figure S1:** One time change in categorical UACR from baseline to end of trial (EOT) in dapagliflozin vs. placebo arm. A. Improvement in UACR categories B. Deterioration in UACR categories

1. **Improvement**




1. **Deterioration**



**Figure S2**: Deterioration in categorical albuminuria status over time (Kaplan-Meier estimate):


1. New onset of >15 mg/g in patients with ≤15 mg/g at baseline
2. New onset of >=30 mg/g in patients with <30 mg/g at baseline
3. New onset of >300 mg/g in patients with <=300 mg/g at baseline

A-



P=0.0536

B-



C-



P<0.0001